RT Journal Article
SR Electronic
A1 Nierengarten, Mary Beth
T1 RISCIS: Phase 3 Trial on Off-Label Use of Riluzole for SCI
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 14
IS 50
SP 14
OP 15
DO 10.1177/155989771450011
UL http://mdc.sagepub.com/content/14/50/14.2.abstract
AB Acute spinal cord injury (SCI) is a devastating injury that can be the result of varying traumatic mechanisms. While early surgical decompression and different pharmacological agents have been advocated over the years, it is still unclear how effective these treatments are in improving neurological outcomes. This article discusses the ongoing Riluzole in Spinal Cord Injury Study [RISCIS; NCT01597518], a phase 3, multicenter, double-blind, randomized controlled trial to evaluate the efficacy and safety of off-label use of riluzole to treat patients with acute SCI.